Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression
Sign Up to like & getrecommendations! Published in 2020 at "Medical Oncology"
DOI: 10.1007/s12032-020-01350-4
Abstract: Lenvatinib is a long-awaited alternative to sorafenib for the first-line targeted therapy of patients with advanced hepatocellular carcinoma (HCC). However, resistance to lenvatinib has also become a major obstacle to improving the prognosis of HCC… read more here.
Keywords: hcc; met expression; hgf met; lenvatinib resistance ... See more keywords
Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Autophagy"
DOI: 10.1080/15548627.2022.2117893
Abstract: ABSTRACT Drug resistance has greatly limited the clinical efficacy of lenvatinib in hepatocellular carcinoma (HCC). However, the underlying molecular mechanisms of lenvatinib resistance remain largely undetermined. Further in-depth exploration of mechanisms underlying lenvatinib resistance is… read more here.
Keywords: lenvatinib resistance; hepatocellular carcinoma; hcc; resistance ... See more keywords
Abstract 1739: Reversal of lenvatinib resistance by curcumin via EGFR signaling pathway in hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-1739
Abstract: Background: Patients with unresectable advanced hepatocellular carcinoma (HCC) are often treated with systemic therapies, and lenvatinib is currently used as one of the first-line therapies. However, the overall response rate from lenvatinib treatment is only… read more here.
Keywords: cell; hepatocellular carcinoma; curcumin; resistance ... See more keywords
Abstract 389: Focal adhension kinase (FAK) confers lenvatinib resistance in hepatocellular carcinoma via regulation of lysine deficient protein kinase 1(WNK1)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-389
Abstract: Lenvatinib is a clinically effective multi-kinase inhibitor approved for first-line therapy of advanced hepatocellular carcinoma (HCC). Although resistance against lenvatinib often emerges and limits its anti-tumor activity, the underlying molecular mechanisms involved in endogenous and… read more here.
Keywords: hepatocellular carcinoma; fak; hcc; kinase ... See more keywords
Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Biological Sciences"
DOI: 10.7150/ijbs.69969
Abstract: Background: Lenvatinib is in a first-line therapy for advanced hepatocellular carcinoma (HCC). However, drug resistance is one of the principal obstacles for treatment failure. The molecular mechanism of Lenvatinib resistance has not been well investigated.… read more here.
Keywords: hepatocellular carcinoma; dusp4 deficiency; genome wide; resistance ... See more keywords